US FDA panel 'TIPs' in favor of Novartis' easier-to-use tobramycin
This article was originally published in Scrip
Executive Summary
In a 13-1 vote, the US FDA's Anti-Infective Drugs Advisory Committee on 5 September said Novartis demonstrated adequate evidence of efficacy and safety to support the use of its new inhalation powder form of tobramycin, known as TIP, in managing cystic fibrosis in patients infected with the bacterium Pseudomonas aeruginosa.